Coumba Toure-Kane

Coumba Toure-Kane

Auto-generated profile, based on publicly available information

Coumba Toure-Kane

Institute for Health Research, Epidemiological Surveillance and Training of Senegal, Dakar, Senegal

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in Journal of Virological Methods
Verified
Journal Article
Closed access
CKCoumba Toure Kane
Coumba Toure Kane
HNHalimatou Diop Ndiaye
Halimatou Diop Ndiaye
SDSada Diallo
Sada Diallo
INIbrahima Ndiaye
Ibrahima Ndiaye
AWAbdoulaye Sidibé Wade
Abdoulaye Sidibé Wade
SMSouleymane Mboup
Souleymane Mboup

5 December 2003
Verified
Closed access
MPMartine Peeters
Martine Peeters
CTCoumba Toure-Kane
Coumba Toure-Kane
JNJohn N Nkengasong
John N Nkengasong

30 September 2006 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
FNFabien Roch Niama
Fabien Roch Niama
CTCoumba Toure-Kane
Coumba Toure-Kane
NVNicole Vidal
Nicole Vidal
POPani Obengui
Pani Obengui
BBBlaise Bikandou
Blaise Bikandou
SMSouleymane Mboup
Souleymane Mboup

5 February 2019 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
ACAbdoul-Magib Cissé
Abdoul-Magib Cissé
GLGabrièle Laborde-Balen
Gabrièle Laborde-Balen
KKKhady Kébé-Fall
Khady Kébé-Fall
ADAboubacry Dramé
Aboubacry Dramé
HDHalimatou DIOP-NDIAYE
Halimatou DIOP-NDIAYE
CTCoumba Touré-Kane
Coumba Touré-Kane
In Senegal in 2015, an estimated 4800 children were living with HIV, with 1200 receiving ARV treatment, of whom half had follow-up care in decentralized sites outside Dakar. However, until now no studies have determined the efficacy of pediatric treatment in decentralized settings, even though the emergence of viral resistance, particularly among children in Africa, is a well-known phenomenon. This study aimed to assess the virological status of HIV-infected children in all decentralized facilities to help improve access to quality care. A cross-sectional epidemiological and virological study was conducted in all of Senegal’s regions, except Dakar, between March and June 2015 and sought to include all HIV-infected children and adolescents (0–19 years), treated or not with ARVs. Socio-demographic and clinical data and a blood sample on blotting paper were collected for children from treatment sites. Samples were routed on public transportation, assisted by a network of community health workers. A viral load (VL) assay was performed for each child, followed by genotyping when it exceeded 1000 copies/mL (3 log10). Of the 851 identified children, 666 (78%) were enrolled in the study. Half of the children were girls, and the average age was 8 years (6 months–19 years). Most of the children (96.7%) were infected with HIV-1, and 90% were treated with ART, primarily with AZT + 3TC + NVP/EFV therapeutic regimen. The median duration of time on ART was 21 months (1–129). VL was measured for 2% of children before this study. Almost two-thirds (64%) of the children are experiencing virological failure. Among them, there was resistance to at least one drug for 86.5% of cases. Also, 25% children presented resistance to one drug and 40% to two out of three. For nearly one-third of the children presenting resistance, none of the three drugs of the treatment was active. Factors associated with virological failure were male sex, follow-up by a generalist rather than a specialist, and treatment interruptions. We observed a high level of virological failure and a high percentage of viral resistance among children receiving health care in decentralized facilities in Senegal.

1 November 2009 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
CKC Toure Kane
C Toure Kane
SDS Diawara
S Diawara
HNH D Ndiaye
H D Ndiaye
PDP A N Diallo
P A N Diallo
AWA S Wade
A S Wade
SMS Mboup
S Mboup
The objective of this article is to report seroprevalences on HIV and herpes simplex virus 2 (HSV-2) in female sex workers (FSW) and in two sentinel populations of pregnant women living in Senegal. Serosurveys of HIV and HSV-2 were conducted in two unselected sentinel populations from Dakar, Senegal, and its provinces, including in 2003 only pregnant women and 2006 pregnant women and FSW. The population study involved 888 pregnant women and 604 FSW. In pregnant women, HIV and HSV-2 seroprevalences were, respectively, 1.01% and 15.65%. There was no association between HSV-2 and HIV infection, whatever the age. In contrast, the seroprevalence of HIV infection in the group of FSW was high, reaching 22.9% in women over 30 years old. FSW above 20 years of age harboured much higher HSV-2 seroprevalences that those found in pregnant women of similar age groups. In FSW, strong associations between HSV-2 and age, and among HSV-2 and HIV-1 as well HIV-2, were evidenced. In conclusion, HIV epidemic remains concentrated in high-risk groups of the Senegalese population, such as the FSW population in which the seroprevalence of HSV-2 infection is very high. Intervention against STI including HSV-2 is urgently needed to prevent the spreading of HIV epidemic.

1 January 2014 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
ADAbou Abdallah Malick DIOUARA
Abou Abdallah Malick DIOUARA
HDHalimatou DIOP-NDIAYE
Halimatou DIOP-NDIAYE
IGIbrehima Guindo
Ibrehima Guindo
NBNestor Bangoura
Nestor Bangoura
MCMohamed Cissé
Mohamed Cissé
NKNdèye Coumba Touré Kane
Ndèye Coumba Touré Kane
Introduction: Access to antiretroviral treatment (ART) becomes more and more effective in resource‐limited settings (RLS). However, this global effort would be even more profitable if the access to laboratory services especially in decentralized settings was strengthened. We report the virological outcome and HIV‐1 drug resistance in three West African countries using dried blood spots (DBS) samples.Methods: We included HIV‐1‐infected adults on ART ≥6 months and followed up in capital cities and decentralized sites in Senegal, Mali and Guinea‐Conakry. Patients were consecutively enrolled and DBS were collected in field conditions and kept at ambient temperature before transfer to the reference laboratory. Viral load (VL) was quantified using the NucliSENS EasyQ HIV‐1 v1.2. Genotyping of HIV‐1 pol gene was performed using in‐house protocol.Results: Of the 407 participants, 119, 152 and 136 were from Senegal, Mali and Guinea‐Conakry, respectively. The median treatment duration was 36 months [IQR: 6–136]. Virological failure (VF) (VL≥3log10 copies/mL) was observed in 26% (95% confidence interval (CI), 18–35; n=31), 11% (95% CI, 6–17; n=16) and 24% (95% CI, 17–32; n=33) of patients in Senegal, Mali and Guinea‐Conakry, respectively (p=0.001). Of samples presenting VL≥3log10 copies/mL (n=80), 70 were successfully genotyped. At least one drug resistance mutation (DRM) was detected in the following proportions: 70% (95% CI, 50–86; n=19), 93% (95% CI, 68–100; n=14) and 68% (95% CI, 48–84; n=19) in Senegal, Mali and Guinea‐Conakry, respectively (p=0.22). Twenty‐six per cent (26%; 95% CI, 16–38; n=18) of patients in VF harboured wild‐type viruses, which is likely indicative of weak adherence. Phylogenetic analysis showed the predominance of CRF02_AG subtype (73%; 95% CI, 61–83; n=51).Conclusions: We describe the ART outcome in capital and rural settings of Senegal, Mali and Guinea‐Conakry. Our results in all of the three countries highlight the need to reinforce the ART adherence in order to minimize the occurrence of drug resistance. In addition, these findings provide additional evidence that the use of DBS as a sampling support could assist virological monitoring of patients on ART in remote areas.